STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Feb. 28, 2025	Feb. 29, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,386,207)	$ (1,335,431)
Adjustments to reconcile net loss to net cash used by operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.	981,625	799,879
Changes in operating assets and liabilities
Prepaids	1,000
Accounts payable	8,007	(3,560)
Accrued liabilities	7,044	15,332
NET CASH USED BY OPERATING ACTIVITIES	(388,531)	(523,780)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	388,068	524,156
NET CASH PROVIDED BY FINANCING ACTIVITIES	388,068	524,156
NET INCREASE (DECREASE) IN CASH	(463)	376
CASH AT BEGINNING OF PERIOD	1,310	934
CASH AT END OF PERIOD	$ 847	$ 1,310